PBYI Quote, Financials, Valuation and Earnings

Relmada Therapeutics, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of --. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Relmada Therapeutics, Inc.'s return on equity of -214.4%.

Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -33.84%. On the other hand Relmada Therapeutics, Inc. has an analysts' consensus of $1.00 which suggests that it could grow by 37.5%. Given that Relmada Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.177, which suggesting that the stock is 17.656% more volatile than S&P 500. In comparison Relmada Therapeutics, Inc. has a beta of 0.740, suggesting its less volatile than the S&P 500 by 25.972%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Relmada Therapeutics, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are larger than Relmada Therapeutics, Inc. quarterly revenues of --. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Relmada Therapeutics, Inc.'s net income of -$10.1M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 7.14x while Relmada Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.25x versus -- for Relmada Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Syndax Pharmaceuticals, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of -132.36%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Syndax Pharmaceuticals, Inc.'s return on equity of -136.36%.

Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -33.84%. On the other hand Syndax Pharmaceuticals, Inc. has an analysts' consensus of $39.31 which suggests that it could grow by 99.13%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.177, which suggesting that the stock is 17.656% more volatile than S&P 500. In comparison Syndax Pharmaceuticals, Inc. has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.361%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Syndax Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are larger than Syndax Pharmaceuticals, Inc. quarterly revenues of $45.9M. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Syndax Pharmaceuticals, Inc.'s net income of -$60.7M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 7.14x while Syndax Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.25x versus 15.26x for Syndax Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of -40.15%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -33.84%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 125.96%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.177, which suggesting that the stock is 17.656% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 7.14x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.25x versus 1.44x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of 34.76%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -33.84%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $485.36 which suggests that it could grow by 6.12%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.177, which suggesting that the stock is 17.656% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Puma Biotechnology, Inc.'s net income of $8.8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 7.14x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.25x versus 10.10x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.